Statistics from Altmetric.com
QUESTION: In pregnant women with preterm, prelabour rupture of fetal membranes (pPROM), are antibiotics better than placebo for preventing neonatal death, chronic lung disease, or major cerebral abnormality before discharge?
161 centres in 15 countries.
4826 pregnant women who had fetuses that were <37 weeks of gestation, had pPROM, and had an uncertain need for antibiotics. Women who would have immediate or unstoppable delivery or who had fetuses not premature enough to warrant concern, had medical or drug contraindications, were prescribed antibiotics, or who were to be prescribed antibiotics for infection were excluded. 4809 women (mean age 28 y) were studied after exclusion of 15 women for protocol violations and 2 women for loss to follow up.
1197 women were allocated to erythromycin, 250 mg; 1212 were allocated to co-amoxiclav, 325 mg (composed of amoxicillin, 250 mg, plus clavulanic acid, 125 mg); 1192 were allocated to combined co-amoxiclav, 325 mg, and erythromycin, 250 mg; and 1225 were allocated to placebo. All treatments were taken orally 4 times daily for 10 days or until delivery.
Main outcome measure
Composite measure of neonatal death, chronic lung disease (received daily supplementary oxygen at 36 weeks after conception), or major cerebral abnormality on ultrasonography before discharge.
Analysis was by intention to treat. Erythromycin, co-amoxiclav, and combined treatments were not better than placebo for preventing occurrence of the composite measure before discharge (table).
In pregnant women with preterm, prelabour rupture of fetal membranes, erythromycin, co-amoxiclav, or combined treatments were not better than placebo for preventing the composite outcome measure of neonatal death, chronic lung disease, or major cerebral abnormality before discharge.
At the beginning of the 21st century, preterm delivery remains the major perinatal challenge. Even mild and moderate preterm birth infants are at high relative risk for death.1 Widespread uncertainty exists about the benefits and risks of antibiotic use for women in spontaneous labour with intact membranes and for those with pPROM. The findings of these studies by Kenyon et al (ORACLE I and II) are therefore highly relevant to practitioners and those planning future research.
The authors have enrolled unprecedented numbers of women in preterm labour in their placebo controlled trial (>4 times the number of women included in all previous randomised controlled trials in this area). Details are not given, however, of eligible patients who were not offered or who declined entry to the trial, and information is not available about the proportions of women in participating hospitals who were considered ”ineligible” because antibiotics had already been prescribed or were considered necessary. If large numbers of women were already receiving antibiotics, this would limit the generalisability of the results, with those entered in ORACLE possibly representing a group who were “less at risk.” This possibility may explain the finding that two thirds of the mothers in ORACLE II delivered at term as well as the finding of low overall mortality (about 2.5%). In previous studies on antibiotics in preterm labour cited in the Cochrane review, the overall mortality was 15%.2 Use of a predictive test, such as fetal fibronectin, may have allowed identification of a higher risk group. However, in ORACLE I, in which the entry criterion of “ruptured membranes” was more clearly defined, the mortality rate was about 6.3%, which compares with the meta-analysed rate of 7.6%.3
Groups did not differ for the main outcome in either ORACLE I or II. Secondary analyses in women with pPROM suggested several benefits. Although these findings may indeed be the result of chance,4 they mirror trends seen in the meta-analysis.3 Given the growing body of evidence that intrauterine infection is linked to long term adverse outcome and the absence of findings to show harm associated with erythromycin treatment, it is highly likely that prophylactic treatment in this situation will become standard. Similarly, clinicians would be wise to avoid the use of augmentin (co-amoxiclav) in these situations.
The authors, in discussing the negative findings of ORACLE II, suggest future research in relation to screening for bacterial vaginosis and subsequent antibiotic treatment. It is worth noting that another trial with negative results has recently been published.5
Sources of funding: UK Medical Research Council. Co-amoxiclav (Augmentin) and co-amoxiclav placebo were supplied by SmithKline Beecham; erythromycin (Erymax) and erythromycin placebo were supplied by Parke Davis.
For correspondence: Ms S Kenyon, Department of Obstetrics and Gynaecology, Robert Kilpatrick Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UK. Fax +44 (0)116 252 3154.
↵† Information provided by author.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.